Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.24
IRWD's Cash to Debt is ranked lower than
59% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. IRWD: 1.24 )
Ranked among companies with meaningful Cash to Debt only.
IRWD' s 10-Year Cash to Debt Range
Min: 1.1  Med: 170.95 Max: N/A
Current: 1.24
Equity to Asset 0.22
IRWD's Equity to Asset is ranked lower than
92% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IRWD: 0.22 )
Ranked among companies with meaningful Equity to Asset only.
IRWD' s 10-Year Equity to Asset Range
Min: -1.86  Med: 0.48 Max: 0.74
Current: 0.22
-1.86
0.74
F-Score: 4
Z-Score: -0.80
M-Score: 20.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -168.63
IRWD's Operating margin (%) is ranked lower than
91% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. IRWD: -168.63 )
Ranked among companies with meaningful Operating margin (%) only.
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36  Med: -199.39 Max: -48.43
Current: -168.63
-1101.36
-48.43
Net-margin (%) -190.84
IRWD's Net-margin (%) is ranked lower than
92% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. IRWD: -190.84 )
Ranked among companies with meaningful Net-margin (%) only.
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31  Med: -224.96 Max: -48.34
Current: -190.84
-1192.31
-48.34
ROE (%) -145.40
IRWD's ROE (%) is ranked lower than
97% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.03 vs. IRWD: -145.40 )
Ranked among companies with meaningful ROE (%) only.
IRWD' s 10-Year ROE (%) Range
Min: -299.34  Med: -178.17 Max: -48.14
Current: -145.4
-299.34
-48.14
ROA (%) -48.79
IRWD's ROA (%) is ranked lower than
93% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. IRWD: -48.79 )
Ranked among companies with meaningful ROA (%) only.
IRWD' s 10-Year ROA (%) Range
Min: -107.22  Med: -39.28 Max: -22.85
Current: -48.79
-107.22
-22.85
ROC (Joel Greenblatt) (%) -459.67
IRWD's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. IRWD: -459.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -672.27  Med: -258.80 Max: -190.56
Current: -459.67
-672.27
-190.56
Revenue Growth (3Y)(%) -5.30
IRWD's Revenue Growth (3Y)(%) is ranked lower than
79% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. IRWD: -5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IRWD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -33.60 Max: -5.3
Current: -5.3
EBITDA Growth (3Y)(%) 27.50
IRWD's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 482 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.40 vs. IRWD: 27.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IRWD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -57.90 Max: 52
Current: 27.5
0
52
EPS Growth (3Y)(%) 28.80
IRWD's EPS Growth (3Y)(%) is ranked higher than
81% of the 450 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IRWD: 28.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IRWD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -56.40 Max: 54.3
Current: 28.8
0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

IRWD Guru Trades in Q2 2014

Joel Greenblatt 27,789 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

IRWD Guru Trades in Q3 2014

Steven Cohen 1,292,500 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
Joel Greenblatt Sold Out
» More
Q4 2014

IRWD Guru Trades in Q4 2014

Steven Cohen 1,500,100 sh (+16.06%)
Vanguard Health Care Fund 4,166,598 sh (+6.79%)
» More
Q1 2015

IRWD Guru Trades in Q1 2015

Vanguard Health Care Fund 4,231,687 sh (+1.56%)
Steven Cohen 750,000 sh (-50.00%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 416.67
IRWD's Forward P/E is ranked lower than
99% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.98 vs. IRWD: 416.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 25.32
IRWD's P/B is ranked lower than
97% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. IRWD: 25.32 )
Ranked among companies with meaningful P/B only.
IRWD' s 10-Year P/B Range
Min: 5.46  Med: 10.58 Max: 46.91
Current: 25.32
5.46
46.91
P/S 18.70
IRWD's P/S is ranked lower than
90% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.27 vs. IRWD: 18.70 )
Ranked among companies with meaningful P/S only.
IRWD' s 10-Year P/S Range
Min: 2.65  Med: 22.02 Max: 75.05
Current: 18.7
2.65
75.05
Current Ratio 4.41
IRWD's Current Ratio is ranked higher than
73% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. IRWD: 4.41 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s 10-Year Current Ratio Range
Min: 2.33  Med: 4.41 Max: 9.64
Current: 4.41
2.33
9.64
Quick Ratio 4.33
IRWD's Quick Ratio is ranked higher than
76% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. IRWD: 4.33 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s 10-Year Quick Ratio Range
Min: 2.33  Med: 4.21 Max: 9.04
Current: 4.33
2.33
9.04
Days Inventory 183.04
IRWD's Days Inventory is ranked lower than
78% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.04 vs. IRWD: 183.04 )
Ranked among companies with meaningful Days Inventory only.
IRWD' s 10-Year Days Inventory Range
Min: 193.31  Med: 730.81 Max: 1266.91
Current: 183.04
193.31
1266.91
Days Sales Outstanding 3.47
IRWD's Days Sales Outstanding is ranked higher than
97% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.21 vs. IRWD: 3.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s 10-Year Days Sales Outstanding Range
Min: 0.05  Med: 16.14 Max: 889.76
Current: 3.47
0.05
889.76

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 63.95
IRWD's Price/Net Current Asset Value is ranked lower than
97% of the 377 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.83 vs. IRWD: 63.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 7.89  Med: 14.36 Max: 228.56
Current: 63.95
7.89
228.56
Price/Tangible Book 25.31
IRWD's Price/Tangible Book is ranked lower than
95% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. IRWD: 25.31 )
Ranked among companies with meaningful Price/Tangible Book only.
IRWD' s 10-Year Price/Tangible Book Range
Min: 5.99  Med: 9.64 Max: 36.28
Current: 25.31
5.99
36.28
Price/Median PS Value 0.86
IRWD's Price/Median PS Value is ranked higher than
82% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. IRWD: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 0.96 Max: 2.9
Current: 0.86
0.14
2.9
Earnings Yield (Greenblatt) (%) -9.03
IRWD's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. IRWD: -9.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IRWD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -10.1  Med: 0.00 Max: 0
Current: -9.03
-10.1
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 25 2015
Ironwood Pharmaceuticals Whittled Down Jun 18 2015
Edited Transcript of EXAS earnings conference call or presentation 4-May-15 2:00pm GMT Jun 16 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 15 2015
Edited Transcript of IRWD presentation 10-Jun-15 8:20pm GMT Jun 11 2015
One Of Mark Lampert’s Small-Cap Biotech Picks Has Returned 84% This Year And It’s Not Done Yet Jun 10 2015
Ironwood Pharmaceuticals Prices $300 Million of Convertible Senior Notes Jun 10 2015
Ironwood Pharmaceuticals Prices $300 Million of Convertible Senior Notes Jun 10 2015
Ironwood Pharmaceuticals Announces Proposed Offering of $300 Million of Convertible Senior Notes Jun 08 2015
Ironwood Pharmaceuticals Announces Proposed Offering of $300 Million of Convertible Senior Notes Jun 08 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 05 2015
Ironwood Pharmaceuticals to Present at Goldman Sachs 36th Annual Global Healthcare Conference Jun 04 2015
Ironwood Pharmaceuticals to Present at Goldman Sachs 36th Annual Global Healthcare Conference Jun 04 2015
IRONWOOD PHARMACEUTICALS INC Financials May 15 2015
Ironwood Presents Gastrointestinal Disease Research at Digestive Disease Week® 2015 May 13 2015
Ironwood Presents Gastrointestinal Disease Research at Digestive Disease Week® 2015 May 13 2015
10-Q for Ironwood Pharmaceuticals, Inc. May 08 2015
IBS in America: American Gastroenterological Association Initiates Comprehensive Survey of Patients... May 08 2015
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference May 07 2015
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK